Resistance Plus® GC

N. gonorrhoeae + ciprofloxacin susceptibility

Smarter Diagnostics. Simplified Patient Care.



Up to 70%[†] of gonorrhoea infections could be treated with ciprofloxacin, a simple oral antibiotic.¹⁻⁴

- Guidelines for gonococcal infection (GC) management call to preserve ceftriaxone,⁵ and allow use of ciprofloxacin when susceptibility information is available.^{5,6}
- Azithromycin resistance is rising, compromising dual-therapy options.^{5,7,8}
- Ciprofloxacin has higher efficacy for pharyngeal infections, a site where ceftriaxone is less effective.^{9,10}





Resistance Plus® GC is a multiplex qPCR test for detection of Neisseria gonorrhoeae and gyrA markers linked to ciprofloxacin susceptibility. Dual N. gonorrhoeae targets improve clinical specificity, while ciprofloxacin resistance and susceptibility targets are included for additional confidence. Resistance Plus® GC is validated for a range of specimen types and powered by proprietary PlexPCR® technologies demonstrating improved multiplex performance compared with other probe-based tests. 15

Single-well **Plex**PCR® test

| Channel | Target | |
|---------|-----------------------|--|
| 1 | N. gonorrhoeae (opa) | |
| 2 | N. gonorrhoeae (porA) | |
| 3 | gyrA S91F mutation | |
| 4 | gyrA S91 wild type | |
| 5 | Internal Control | |

SpeeDx Analysis for ResistancePlus® GC

Improve laboratory productivity with a validated software solution for automated result calling and simple data processing. Streamlined workflow to support rapid, routine diagnostics with audit trails and user traceability. Included in contract pricing and installed on a high security and GDPR compliant platform, with LIS compatibility.

Demonstrated clinical performance¹⁴

| | GC Detection | gyrA Detection |
|-------------|-----------------|-------------------|
| Sensitivity | 91.5% | 100% |
| Specificity | 100% | 100% |

Validated for urine, swabs (anal, rectal, cervical, vaginal, urethral, pharyngeal, eye) and extracts. 14

- ➤ A unique triple target, single-well test solution, ideal for confirming GC positives or for upfront testing with simultaneous resistance status.
- Genotype confirmation to inform ciprofloxacin susceptibility as an alternative treatment pathway.
- Easily obtain resistance/susceptibility data on difficult to culture specimen types.
- Positive, negative, and amplification control materials available.

| Product | Compatible | Size | Cat# |
|---|--------------------------------|---------------|-------------|
| Resistance Plus [®] GC* | LightCycler® 480 Instrument II | 100 reactions | 09257241001 |
| ResistancePlus® GC Control | LightCycler® 480 Instrument II | 10 reactions | 09257225001 |
| PlexPCR® Amplification Control | LightCycler® 480 Instrument II | 400 reactions | 09256687001 |

References: 1. Harris SR et al. Lancet Infect Dis 2018; 18: 758-68. 2. Lahra MM et al. Commun Dis Intell Q Rep. 2017;41 (1): E. 3. Heffeman H et al. Antimicrobial resistance and molecular epidemiology of gonococci in NZ, 2014-54. Kirkcaldy RD et al. MMWR Surveillance Summaries 2016 Jul 15:65(7): 1-19. 5. Fifer H. et al. Int J STD AIDS. 2020;31 (1):4-15. 6. Bignell C, et al. Int J STD AIDS. 2013;24(2):85-92. 7. Wi T et al. PLoS Med 2017;14(7):e1002344. 8. Bolt H et al. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/567602/GRASP_Report_2016.pdf 9. Lewis DA. Sex Transm Infect 2015;91:234-237. 10. Whittles LK et al. Lancet Infect Dis. 2018 Jul;18(7):716-717. 11. Allan-Blitz LT et al. Sex Transm Dis. 2017 May;44(5):261-265. 12. Trembizki E et al. Lancet Infect Dis. 2016 Sep;16(9):1005-1006. 13. Allan-Blitz LT et al. Clin Infect Dis. 2017 May;164(9):1268-1270. 14. ResistancePlus® GC Instructions for use 15. Tan LY et al, PLOS ONE. 2017; 12(1): e0170087.

‡Susceptibility rates vary by population and/or region.

ResistancePlus® GC kits are developed and manufactured by SpeeDx Pty Ltd, Sydney. PlexPCR® & ResistancePlus® are trademarks of SpeeDx Pty Ltd. Other copyright and trademarks are the property of the respective owners. SpeeDx Pty Ltd products may be covered by one or more local or foreign patents. Visit www.plexpcr.com/patents for comprehensive patent information.

Manufactured by:

SpeeDx Pty. Ltd.

Suite G16, National Innovation Centre 4 Cornwallis Street, Sydney NSW 2015 Australia

plexpcr.com

Distributed by:

Roche Molecular Solutions

4300 Hacienda Drive Pleasanton, CA 94588 USA

diagnostics.roche.com



^{*}Not for sale in USA.